On September 30, Arrowhead Pharmaceuticals fell 6.35% in pre-market trading, trading at $66.86 USD/share, with Turnover of $2,542.03.

Within the Biotechnology sector where Arrowhead Pharmaceuticals belongs, the overall sector performance was mixed. Among individual stocks, Moderna up 0.33%, Amgen up 0.24%, Iovance Biotherapeutics down 1.31%, AbbVie up 0.21%, Natera up 0.73%.

Arrowhead Pharmaceuticals develops medicines based on RNA interference mechanisms, silencing disease-causing genes to treat intractable diseases. The company currently has 18 drug candidates across early-to-late-stage clinical trials and recently secured EU marketing authorization for Redemplo (Plozasiran) to treat Familial Chylomicronaemia Syndrome, with plans to submit a supplemental new drug application to the FDA by year-end using a priority review voucher.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)